ClinicalTrials.gg
CompletedNCT03479437Updated May 4, 2021

The TEMPO (Tracing the Effect of the MC4 Pathway in Obesity) Registry

An observational study in Genetic Forms of Extreme Obesity, sponsored by Rhythm Pharmaceuticals, Inc.. Completed at 2 sites in 2 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2021-05-04.

Sponsored by Rhythm Pharmaceuticals, Inc. · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
303
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 19 studies in Obesity by Rhythm Pharmaceuticals, Inc. — none open to participants now, 2 under way, none of them phase 3. Obesity · Rhythm Pharmaceuticals, Inc..

Started
2018
with 3 others
Observational
2 of 19
none open now
Registered
10th of 19
by date

Among the 19 studies in Obesity by Rhythm Pharmaceuticals, Inc., this one is one of 4 that started in 2018, is one of 2 observational ones, and was the 10th registered.

Obesity

11,547 studies on the registry are indexed under Obesity; 2,050 are open to participants now.

Browse Obesity studies →

Open to participants now

None of the 19 studies in Obesity by Rhythm Pharmaceuticals, Inc. is open now. The open studies under Obesity, anywhere →

Who these studies take

Of the 1,343 Obesity studies recruiting now, 377 (28%) set no upper age limit and 862 (64%) stop at 75 or younger; 168 take children under 18; 488 take healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies in Obesity by Rhythm Pharmaceuticals, Inc. as a file.
02

Study summary

A voluntary prospective study that will allow registration and follow-up of individuals with MC4R pathway genetic obesity.

Read the detailed description

Potential patients will be referred to coordinating centers by their healthcare provider (treating physician, diagnosing physician or primary care physician) and if eligible will be invited to enroll in the registry. The Registry Coordinating Center will be responsible for obtaining consent from adult patients and caregivers of minor patients (as well as assent from minors when appropriate), screening patients and enrolling them in the registry.

The registry will capture data entered by the patient, the patient's healthcare provider, and the patient's caregiver using online (electronic) survey tools administered at baseline, and annually thereafter. The patient's healthcare provider will complete the baseline Healthcare Provider survey tool, reporting the patient's baseline demographics, medical history, clinical information, and disease characteristics. The patient and caregiver will complete their dedicated baseline survey tools answering questions on the impact of disease on their everyday life. Survey tools include questions on patient and caregiver demographics, patient physical activity, patient food and hunger episodes, patient quality of life, and caregiver's perspective of disease burden on the family. Registry patients, caregivers, and healthcare providers will be contacted annually (approximately every 12 months) by the Registry Coordinating Center to complete an online follow-up survey tool including a smaller subset of questions from the baseline survey tools.

03

Conditions studied

  • Genetic Forms of Extreme Obesity

Browse trials for

Keywords

  • Obesity
  • Melanocortin
  • TEMPO
  • MC4R
  • Genetic Obesity
  • hypothalamic
  • POMC
  • LEPR
  • PCSK1
04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Extreme obesity in adults age 18 or older defined as a BMI >40 kg/m2 or subjects from age 2 through age 18 years with a BMI value that is >1.4 times the corresponding age/gender 95th percentile value will be eligible.

Second, specific genotypic criteria involving defined major genes contributing to genetic obesity disorders will also be required for enrollment.

Patients will be eligible to participate in the registry regardless of gender or geographic location. Other genetic forms of obesity may be added to this list as pathogenetic etiologies and the potential involvement of specific genes in the hypothalamus upstream or downstream of the MC4R become better understood.

All known patients, or their caregivers, will be invited to participate. As new patients resulting from novel gene variants or defects are identified, registry patient enrollment will continue on an ongoing basis.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Extreme obesity patients aged 2 years and older.
  2. Extreme obesity defined as:

    1. > 40 kg/m2 in patients 18 years of age or older.
    2. BMI value that is >1.4 times the corresponding age/gender 95th percentile value in patients who are 2 through 17 years of age.
  3. At least one of the following genotypes:

    1. Bi-allelic (homozygous or compound heterozygous) POMC, PCSK1, LEPR variants leading to the physician-confirmed diagnosis of either POMC or LEPR deficiency obesity.
    2. The presence of high-confidence, high-impact genetic variations (homozygote, compound heterozygote, heterozygote or composite heterozygote [i.e., heterozygous variants in more than a single gene]) in these same 3 genes (POMC, PCSK1 and LEPR) associated with the clinical presentation of extreme obesity
    3. The presence of other high-confidence, high-impact genetic variations (homozygote, compound heterozygote, heterozygote or composite heterozygote in the MC4R gene or other upstream MC4R-pathway genes and selected variants downstream in the MC4R-pathway (Table 1) that are carried by extreme obesity patients who do not demonstrate specific syndromic obesity clinical presentations. Selected Bardet-Biedl syndrome (BBS1 through BBS21) genetic variants or Alström syndrome (ALMS) genetic variants possibly contributing to non-syndromic forms of clinical extreme obesity will be eligible for enrollment.
  4. Study participant and/or parent or caregiver can understand and comply with the requirements of the study, and able to understand and sign the written (IC)/assent, after being informed about the study.

Exclusion criteria

Exclusion Criteria:

  1. Patients with syndromic forms of obesity such as Bardet-Biedl syndrome or Alström syndrome. These patients will be referred to existing registries for these specific syndromic obesity (e.g., Clinical Registry in Bardet-Biedl syndrome [CRIBBS] for BBS patients).
  2. Individual is, in the opinion of the study investigator, not suitable to participate in the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
303 participants (actual)
Target follow-up
5 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Assessment of Quality of Life

    Evaluate the quality of life through annual patient and caregiver reported surveys.

    Time frame: 5 years

07

Study locations

2 sites
  • Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
  • University of Alberta
    Edmonton, T6G 2B7, Canada
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in Dec 2020, 31 months.

Of 46 industry-sponsored observational studies under Obesity, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 45. This study's 31 months is above that.

Counting every sponsor, half of 839 studies reached it within 39 months; a quarter within 17 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2018
First posted
Mar 27, 2018
StartActual
Apr 15, 2018
Primary completionActual
Dec 1, 2020
CompletionActual
Dec 1, 2020
Last update
May 4, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03479437
Responsible party
Sponsor
First posted
Mar 27, 2018
Start date
Apr 15, 2018
Primary completion
Dec 1, 2020
Completion
Dec 1, 2020
Last update
May 4, 2021

Study contacts

Ihuoma Eneli
principal investigator · Nationwide Children's Hospital
Liz Stoner
study chair · Rhythm Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion